Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment

J Clin Oncol. 2011 Apr 20;29(12):e333-5. doi: 10.1200/JCO.2010.32.5928. Epub 2011 Jan 24.

Authors

Sarina A Piha-Paul¹, David S Hong, Razelle Kurzrock

Affiliation

¹ University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 21263090
DOI: 10.1200/JCO.2010.32.5928

No abstract available

Publication types

Case Reports

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Biopsy
Female
Humans
Lymphangioleiomyomatosis / diagnosis
Lymphangioleiomyomatosis / drug therapy*
Lymphangioleiomyomatosis / enzymology
Middle Aged
Protein Kinase Inhibitors / administration & dosage
Retroperitoneal Neoplasms / diagnosis
Retroperitoneal Neoplasms / drug therapy*
Retroperitoneal Neoplasms / enzymology
Sirolimus / administration & dosage
Sirolimus / analogs & derivatives
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / metabolism
Tomography, X-Ray Computed
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Protein Kinase Inhibitors
Bevacizumab
temsirolimus
MTOR protein, human
TOR Serine-Threonine Kinases
Sirolimus